KRAS and colorectal carcinoma: The immune response in KRAS mutant CRC was heterogeneous, with CMS2 KRAS mutant samples exhibiting the lowest CIRC expression, reduced interferon gamma pathway expression, STAT1, CXCL10, and decreased infiltration of cytotoxic cells and neutrophils compared to CMS1, CMS4, and CMS2 KRAS wild-type samples in the TCGA dataset [108].